Relamorelin, a ghrelin agonist, led to both symptomatic improvement and acceleration of gastric emptying in three studies, but the subsequent phase 3 trial was terminated prematurely, apparently for commercial reasons [79]
Ongoing trials (NCT03782259, NCT04490681) will provide further evidence about the impact of SGLT2i on ECV
Liposomal and acetylated forms occupy a middle ground: they're better than nothing, they do raise plasma GSH modestly, and some users report subjective benefit
59 Gruber-DorningerC.JenkinsT.SchatzmayrG
To ensure statistical comparability across studies, transformations followed the methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (e.g., converting medians and inter-quartile ranges to means and standard deviations)